Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)

NCT02333071 is registered in ClinicalTrials.gov with Palatin Technologies, Inc as lead sponsor.

NCT NCT02333071
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02333071 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
Lead sponsor
Palatin Technologies, Inc
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2014
Completion date
June 30, 2017
Enrollment
723 (actual)
Sites
91

Conditions

As the registry lists them; a condition with its own page is linked.

hypoactive sexual desire disorder